# Critical evaluation — v0.6.1

The project rule remains: a release without concordance against valid measured therapeutic-antibody
distribution cannot score 8/10 or higher.

| Perspective | Score | Main reason it is not higher |
|---|---:|---|
| Biologics discovery hiring manager | 7.8/10 | Relative external validation is useful, but no dose, format or target decision is supported. |
| Methods reviewer | 7.6/10 | No reaction–diffusion prediction is compared with measured drug concentration or engagement. |
| Skeptical statistician | 7.8/10 | Proxy-definition sensitivity is quantified, but independent biological sample counts remain limited. |
| Software engineer | 8.8/10 | Full strict Mypy and Pyright now pass across the package; provider-format fixtures are still limited. |
| Reproducibility auditor | 8.4/10 | Artifacts and invalid payloads are audited, but the external antibody benchmark remains unavailable. |

**Weighted overall assessment: 7.9/10.**

The engineering dismissal risk has been materially reduced. The scientific dismissal risk is unchanged:
there is still no valid administered-antibody distribution, perfusion marker, receptor-copy calibration
or tissue-specific diffusion measurement. Pharmacological concordance and all real absolute reachability
outputs remain `NOT_COMPUTED`.
